Allogeneic stem cell transplant in a patient with aplastic anemia with bacteremia and candidemia

References (6)

1. Bacigalupo A, Brand R, Oneto R, Bruno B, Socie G, Passweg J, Locasciulli A, Van Lint MT, Tichelli A, McCann S, Marsh J, Ljungman P, Hows J, Marin P, Schrezenmeier H. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immuno-suppressive therapy-The European Group for Blood and Marrow Transplantation experience. Semin Hematol 2000;37:69-80
2. Horowitz MM. Current status of allogenic bone marrow transplantation in acquired aplastic anemia. Semin Hematol 2000;37:30-42
3. Stucki A, Leisenring W, Sandmaier BM, Sanders J, Anasetti C, Storb R. Decreased rejection and improved survival of first and second marrow transplant for severe aplastic anemia (a 26-year retrospective analysis). Blood 1998;92:2742-9
4. Deeg HJ, Leisenring W, Storb R, Nims J, Flowers ME, Witherspoon RP, Sanders J, Sullivan KM. Long-term outcome after marrow transplantation for severe aplastic anemia. Blood 1998;91:3637-45
5. Dvorak CC, Steinbach WJ, Brown JM, Agarwal R. Risks and outcomes of invasive fungal infections in pediatric patients undergoing allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2005 Oct;36:621-9
6. Dulley FL, Vigorito AC, Aranha FJ, Sturaro D, Ruiz MA, Saboya R, Macedo MC, Da Silva RL, Chamone DA, Mehta J, Bacigalupo A, De Souza CA. Addition of low dose cyclophosphamide in aplastic anemia patients prior to allogeneic bone marrow transplantation to reduce rejection. Bone Marrow Transplant 2004;33:9-13.